Xenoestrogen action in prostate cancer: Pleiotropic effects dependent on androgen receptor status

Yelena B. Wetherill, Nicola L. Fisher, Ann Staubach, Mark Danielsen, Ralph W deVere White, Karen E. Knudsen

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Androgen is critical for prostate development, growth, and survival. Therapies for advanced prostate cancer aim to block androgen receptor (AR) action. However, recurrent tumors ultimately arise, which harbor restored AR activity. One mechanism of such reactivation occurs through AR mutations, rendering the receptor responsive to noncanonical ligands. We have shown previously that a known xenoestrogen, bisphenol A (BPA), activates a tumor-derived AR mutant (T877A), leading to androgen-independent prostate cancer cell proliferation. Here, we show that BPA cooperates with androgen to activate AR-T877A as shown by both reporter assays and increased levels of prostate-specific antigen expression. Further investigations using both yeast and mammalian model systems revealed that multiple AR alleles are responsive to BPA, thus expanding the potential influence of xenoestrogens on prostate cancer. Moreover, in vitro radioligand binding assay revealed that BPA alters 5α-dihydrotestosterone binding to AR-T877A likely through noncompetitive inhibition. We also show that higher concentrations of BPA block proliferation of AR-positive, androgen-dependent prostate adenocarcinoma cells (LNCaP and LAPC-4), with a more modest inhibitory effect on androgen-independent cells (22Rv-1). By contrast, AR-negative prostate cancer cells failed to show growth inhibition after exposure to high BPA dose. Together, these data show that BPA can serve as a potential "hormone sensitizer" of the mutant ARs present in advanced prostate adenocarcinomas, thereby possibly contributing toward therapeutic relapse in advanced prostate cancer patients and supporting the notion that nonsteroidal environmental compounds can alter the function of nuclear receptor complexes.

Original languageEnglish (US)
Pages (from-to)54-65
Number of pages12
JournalCancer Research
Volume65
Issue number1
StatePublished - Jan 1 2005
Externally publishedYes

Fingerprint

Androgen Receptors
Prostatic Neoplasms
Androgens
Prostate
Adenocarcinoma
Radioligand Assay
Dihydrotestosterone
Prostate-Specific Antigen
Cytoplasmic and Nuclear Receptors
bisphenol A
Growth and Development
Neoplasms
Yeasts
Alleles
Cell Proliferation
Hormones
Ligands
Recurrence
Mutation
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Wetherill, Y. B., Fisher, N. L., Staubach, A., Danielsen, M., deVere White, R. W., & Knudsen, K. E. (2005). Xenoestrogen action in prostate cancer: Pleiotropic effects dependent on androgen receptor status. Cancer Research, 65(1), 54-65.

Xenoestrogen action in prostate cancer : Pleiotropic effects dependent on androgen receptor status. / Wetherill, Yelena B.; Fisher, Nicola L.; Staubach, Ann; Danielsen, Mark; deVere White, Ralph W; Knudsen, Karen E.

In: Cancer Research, Vol. 65, No. 1, 01.01.2005, p. 54-65.

Research output: Contribution to journalArticle

Wetherill, YB, Fisher, NL, Staubach, A, Danielsen, M, deVere White, RW & Knudsen, KE 2005, 'Xenoestrogen action in prostate cancer: Pleiotropic effects dependent on androgen receptor status', Cancer Research, vol. 65, no. 1, pp. 54-65.
Wetherill YB, Fisher NL, Staubach A, Danielsen M, deVere White RW, Knudsen KE. Xenoestrogen action in prostate cancer: Pleiotropic effects dependent on androgen receptor status. Cancer Research. 2005 Jan 1;65(1):54-65.
Wetherill, Yelena B. ; Fisher, Nicola L. ; Staubach, Ann ; Danielsen, Mark ; deVere White, Ralph W ; Knudsen, Karen E. / Xenoestrogen action in prostate cancer : Pleiotropic effects dependent on androgen receptor status. In: Cancer Research. 2005 ; Vol. 65, No. 1. pp. 54-65.
@article{fe4ea85d5ccd48bd83ed7f948a6a670a,
title = "Xenoestrogen action in prostate cancer: Pleiotropic effects dependent on androgen receptor status",
abstract = "Androgen is critical for prostate development, growth, and survival. Therapies for advanced prostate cancer aim to block androgen receptor (AR) action. However, recurrent tumors ultimately arise, which harbor restored AR activity. One mechanism of such reactivation occurs through AR mutations, rendering the receptor responsive to noncanonical ligands. We have shown previously that a known xenoestrogen, bisphenol A (BPA), activates a tumor-derived AR mutant (T877A), leading to androgen-independent prostate cancer cell proliferation. Here, we show that BPA cooperates with androgen to activate AR-T877A as shown by both reporter assays and increased levels of prostate-specific antigen expression. Further investigations using both yeast and mammalian model systems revealed that multiple AR alleles are responsive to BPA, thus expanding the potential influence of xenoestrogens on prostate cancer. Moreover, in vitro radioligand binding assay revealed that BPA alters 5α-dihydrotestosterone binding to AR-T877A likely through noncompetitive inhibition. We also show that higher concentrations of BPA block proliferation of AR-positive, androgen-dependent prostate adenocarcinoma cells (LNCaP and LAPC-4), with a more modest inhibitory effect on androgen-independent cells (22Rv-1). By contrast, AR-negative prostate cancer cells failed to show growth inhibition after exposure to high BPA dose. Together, these data show that BPA can serve as a potential {"}hormone sensitizer{"} of the mutant ARs present in advanced prostate adenocarcinomas, thereby possibly contributing toward therapeutic relapse in advanced prostate cancer patients and supporting the notion that nonsteroidal environmental compounds can alter the function of nuclear receptor complexes.",
author = "Wetherill, {Yelena B.} and Fisher, {Nicola L.} and Ann Staubach and Mark Danielsen and {deVere White}, {Ralph W} and Knudsen, {Karen E.}",
year = "2005",
month = "1",
day = "1",
language = "English (US)",
volume = "65",
pages = "54--65",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - Xenoestrogen action in prostate cancer

T2 - Pleiotropic effects dependent on androgen receptor status

AU - Wetherill, Yelena B.

AU - Fisher, Nicola L.

AU - Staubach, Ann

AU - Danielsen, Mark

AU - deVere White, Ralph W

AU - Knudsen, Karen E.

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Androgen is critical for prostate development, growth, and survival. Therapies for advanced prostate cancer aim to block androgen receptor (AR) action. However, recurrent tumors ultimately arise, which harbor restored AR activity. One mechanism of such reactivation occurs through AR mutations, rendering the receptor responsive to noncanonical ligands. We have shown previously that a known xenoestrogen, bisphenol A (BPA), activates a tumor-derived AR mutant (T877A), leading to androgen-independent prostate cancer cell proliferation. Here, we show that BPA cooperates with androgen to activate AR-T877A as shown by both reporter assays and increased levels of prostate-specific antigen expression. Further investigations using both yeast and mammalian model systems revealed that multiple AR alleles are responsive to BPA, thus expanding the potential influence of xenoestrogens on prostate cancer. Moreover, in vitro radioligand binding assay revealed that BPA alters 5α-dihydrotestosterone binding to AR-T877A likely through noncompetitive inhibition. We also show that higher concentrations of BPA block proliferation of AR-positive, androgen-dependent prostate adenocarcinoma cells (LNCaP and LAPC-4), with a more modest inhibitory effect on androgen-independent cells (22Rv-1). By contrast, AR-negative prostate cancer cells failed to show growth inhibition after exposure to high BPA dose. Together, these data show that BPA can serve as a potential "hormone sensitizer" of the mutant ARs present in advanced prostate adenocarcinomas, thereby possibly contributing toward therapeutic relapse in advanced prostate cancer patients and supporting the notion that nonsteroidal environmental compounds can alter the function of nuclear receptor complexes.

AB - Androgen is critical for prostate development, growth, and survival. Therapies for advanced prostate cancer aim to block androgen receptor (AR) action. However, recurrent tumors ultimately arise, which harbor restored AR activity. One mechanism of such reactivation occurs through AR mutations, rendering the receptor responsive to noncanonical ligands. We have shown previously that a known xenoestrogen, bisphenol A (BPA), activates a tumor-derived AR mutant (T877A), leading to androgen-independent prostate cancer cell proliferation. Here, we show that BPA cooperates with androgen to activate AR-T877A as shown by both reporter assays and increased levels of prostate-specific antigen expression. Further investigations using both yeast and mammalian model systems revealed that multiple AR alleles are responsive to BPA, thus expanding the potential influence of xenoestrogens on prostate cancer. Moreover, in vitro radioligand binding assay revealed that BPA alters 5α-dihydrotestosterone binding to AR-T877A likely through noncompetitive inhibition. We also show that higher concentrations of BPA block proliferation of AR-positive, androgen-dependent prostate adenocarcinoma cells (LNCaP and LAPC-4), with a more modest inhibitory effect on androgen-independent cells (22Rv-1). By contrast, AR-negative prostate cancer cells failed to show growth inhibition after exposure to high BPA dose. Together, these data show that BPA can serve as a potential "hormone sensitizer" of the mutant ARs present in advanced prostate adenocarcinomas, thereby possibly contributing toward therapeutic relapse in advanced prostate cancer patients and supporting the notion that nonsteroidal environmental compounds can alter the function of nuclear receptor complexes.

UR - http://www.scopus.com/inward/record.url?scp=11244301206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11244301206&partnerID=8YFLogxK

M3 - Article

C2 - 15665279

AN - SCOPUS:11244301206

VL - 65

SP - 54

EP - 65

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 1

ER -